Business
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO Corner Here! THE WOODLANDS, TX, July 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the launch of its CEO Corner featuring Brad Hauser, Chief Executive Officer of Autonomix. The CEO Corner platform is intended to provide additional in-depth perspective to press releases, events, corporate updates and development pipeline progress. “Autonomix and its stakeholders share something in common – generating value in the near and long term for the Company and creating meaningful treatment options for patients. As CEO, I am committed to keeping our stakeholders well informed and maintaining transparency, as I believe it is a key piece to the future success of Autonomix,” commented Brad Hauser. “Our CEO Corner is a new platform for us to do just that in a direct, succinct way with both current and potential investors in the Company. We will utilize our CEO Corner segments to provide added perspective on corporate developments, events, pipeline progress, clinical trials and other company advancements as we continue to drive the Company forward. We are dedicated to the advancement of our technology and will continue to explore ways to drive value in the Company.” The CEO Corner is now accessible on the Company’s website here. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition th...